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Résumé en
anglais
Whereas the angiotensin II type 2 receptor (AT2R) is known to oppose the
proliferative and growth properties of the type 1 receptor, its role in pathological
conditions may be different. Although it is highly expressed in cancer cells, its role
in tumor progression remains poorly understood. We aimed to investigate the
involvement of the AT2R in early tumorigenesis hypothesizing that it may affect
tumor cell proliferation and/or tumor angiogenesis. Tumors were induced with 3-
methylcholanthrene (3-MCA, 20 mg/kg, s.c.) in FVB/N mice lacking the AT2R (AT2R-
KO) or through LL/2 cells injection in C57/BL6N mice treated with the AT2R
antagonist PD123,319. Cell proliferation was evaluated by Ki-67 immunochemistry.
Vascular density was determined using CD31 labelling and angiogenesis was
measured using the aortic ring assay. Tumor initiation by 3-MCA was significantly
delayed in AT2R-KO compared to wild type mice (56 days vs 28 days).
Tumorigenesis following LL/2 cells injection in C57BL/6N mice was significantly
reduced then the AT2R antagonist PD123,319 was given at an early stage of tumor
development, suggesting a role of AT2R in tumor promotion. Moreover, in vitro
proliferation of LL/2 cells was reduced by PD123,319 with a significant decrease in
Ki-67 expression, a marker of cell proliferation. Tumor microvascular density and
angiogenesis were significantly reduced in wild type mice treated with PD123,319
and in AT2R-null mice, compared to control animals. Thus, we showed that the
AT2R has a key role in tumor development, favouring both malignant cell
proliferation and tumor angiogenesis.
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